Factor Viia Affecting Patents (Class 514/14.3)
  • Patent number: 10828350
    Abstract: The present invention provides purified protease inhibitors derived from microorganisms alone or in combination with bacteriocins and/or antibodies. The protease inhibitors may also be expressed by microbiome or probiotic microorganisms alone or in combination with bacteriocins and/or antibodies. The invention also provides methods and compositions for improving the expression of endogenous or heterologous protease inhibitors alone or in combination with bacteriocins and/or antibodies. The invention is useful for treating a variety of inflammatory disorders including acne, psoriasis, eczema, atopic dermatitis and inflammatory bowel disease.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: November 10, 2020
    Inventor: David Gordon Bermudes
  • Patent number: 10538755
    Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: January 21, 2020
    Assignee: OPKO Biologics Ltd.
    Inventors: Udi Eyal Fima, Gili Hart
  • Patent number: 10179905
    Abstract: The present invention relates to the conjugation of Factor VII polypeptides with heparosan polymers. The resultant conjugates may be used to deliver Factor VII, for example in the treatment or prevention of bleeding disorders.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: January 15, 2019
    Assignee: Novo Nordisk Health Care AG
    Inventors: Carsten Behrens, Henrik Oestergaard, Henning Ralf Stennicke
  • Patent number: 10047354
    Abstract: The present application relates to a method of reducing the content of dimers in Factor VII polypeptide composition by heat treatment.
    Type: Grant
    Filed: August 22, 2008
    Date of Patent: August 14, 2018
    Assignee: Novo Nordisk Health Care AG
    Inventor: Janus Krarup
  • Patent number: 9833497
    Abstract: In the invention, the minimum inhibitory concentrations of human-originated EGF domain proteins against different Gram-negative bacteria are detected with the in vitro antibacterial activity. It has been shown that the human-originated EGF domain proteins have an obvious inhibitory effect on the Gram-negative bacteria, so as to develop a novel class of medicaments for treating Gram-negative bacteria infection. It has been demonstrated by silver staining that the human-originated EGF domain proteins have the effect on hydrolyzing and eliminating the endotoxin, which facilitates the development of a novel class of medicaments for treating endotoxemia. The amino acid sequences of the human-originated EGF domain proteins are the one described in SEQ ID NO: 1 in the sequence listing, or those having homology of over 50% to the amino acid sequence described in SEQ ID NO: 1.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: December 5, 2017
    Assignee: Chengdu Sourcebio Limited-Liability Company
    Inventors: Xu Song, Ling Li, Jinwu Chen, Deng Jiao Ma
  • Patent number: 9371355
    Abstract: The present invention relates to a method or process for the manufacture of a virus and prion save native fibrinogen concentrate of high purity and low amounts of fibrinopeptide A and fibronectin.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: June 21, 2016
    Assignee: OCTAPHARMA AG
    Inventors: Petra Schulz, Rainer Pape, Werner Gehringer
  • Patent number: 9023992
    Abstract: The invention described herein provides new methods of preparing purified Factor VII polypeptide drug substances in large quantities (industrial scale levels) that are associated with reduced content of product-related impurities (e.g., late eluting peaks) and/or that exhibit a relatively uniform glycosylation pattern.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: May 5, 2015
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Daniel E. Rasmussen, Janus Krarup
  • Publication number: 20150105321
    Abstract: The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: October 15, 2014
    Publication date: April 16, 2015
    Inventors: Henrik Oestergaard, Prafull S. Gandhi, Ole Hvilsted Olsen
  • Patent number: 8999333
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: April 7, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Patent number: 8865868
    Abstract: The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule, to pharmaceutical compositions comprising the protein conjugates and to the use of the protein conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: October 21, 2014
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Carsten Behrens, Patrick William Garibay, Søren Østergaard, Henrik Sune Andersen, Nils Langeland Johansen, Bernd Peschke, Sonja Bak
  • Patent number: 8859526
    Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: October 14, 2014
    Assignees: Baxter Healthcare S.A., Baxter International Inc.
    Inventor: Kirk W. Johnson
  • Patent number: 8840879
    Abstract: Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a covalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: September 23, 2014
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Wolfram Eichner, Martin Schimmel, Frank Hacket, Elmar Kraus, Norbert Zander, Ronald Frank, Harald Conradt, Klaus Langer, Michele Orlando, Klaus Sommermeyer
  • Patent number: 8765915
    Abstract: The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
    Type: Grant
    Filed: February 3, 2007
    Date of Patent: July 1, 2014
    Assignee: CSL Behring GmbH
    Inventors: Thomas Weimer, Stefan Schulte, Ulrich Kronthaler, Wiegand Lang, Uwe Liebing, Wilfried Wormsbächer
  • Patent number: 8759294
    Abstract: Tissue factor-bearing yeast derived microvesicles comprising a yeast membrane and a tissue factor protein, or a fragment thereof, or a tissue factor protein or a fragment thereof fused to another peptide as a fusion protein having pro-coagulant activity are disclosed. Said products can be used as pro-coagulant agents in the treatment of hemorrhages in a subject.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: June 24, 2014
    Assignee: Thrombotargets Europe, S.L.
    Inventors: Francisco Javier Pedrño Egea, Luis Ignacio Caveda Catasus, Juan Ramón Rodríguez Fernández-Alba
  • Patent number: 8729022
    Abstract: The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: May 20, 2014
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Michael Bech Jensen, Birthe Lykkegaard Hansen, Troels Kornfelt
  • Patent number: 8716448
    Abstract: The present invention relates to compositions comprising factor VII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: May 6, 2014
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem Stemmer, Chia-wei Wang, Benjamin Spink, Nathan Geething, Wayne To
  • Patent number: 8703706
    Abstract: The present invention relates to a closed container holding a composition of an activated Factor VII polypeptide in an amount of in the range of 2.5-90 mg per imL volume of the container. The invention also relates to various processes for the preparation of such closed containers, a kit including such containers and a method of using the kit.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: April 22, 2014
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Anne Charlotte Arentsen, Per Kaersgaard
  • Patent number: 8697844
    Abstract: The invention relates to a method of purifying PEGylated proteins by removing impurities from samples containing PEGylated proteins, in particular, but not exclusively vitamin K-dependent blood coagulation factors such as Factor IX (FIX), to proteins purified by said method and to the use of said purified proteins in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: April 15, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Matthias Karl Dietrich Wiendahl, Lars Sejersgaard, Are Bogsnes
  • Publication number: 20140072600
    Abstract: An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.
    Type: Application
    Filed: March 9, 2012
    Publication date: March 13, 2014
    Inventors: Stefan Zeitler, Marc Nolte, Stafan Schulte, Gerhard Dickneite, Ingo Pragst
  • Patent number: 8658597
    Abstract: The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: February 25, 2014
    Assignee: Novo Nordisk HealthCare AG
    Inventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt
  • Patent number: 8642738
    Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: February 4, 2014
    Assignee: Regents of the University of Minnesota
    Inventor: Gary L. Nelsestuen
  • Patent number: 8536127
    Abstract: Provided are storage containers for proteinaceous pharmaceutical compositions which are characterized in, among other things, comprising (i) a wall portion, wherein an inner wall material thereof is selected from silica-coated glass, silicone-coated glass, polymers of non-cyclic olefins, cycloolefin polymers and cycloolefin/linear olefin copolymers and (ii) one or more closure portions not constituting part of the wall portion, and which contains a formulation of a protein. Also provided are new methods of storing proteinaceous compositions. In one aspect, the stored protein is characterized as having an amino-terminal ?-carboxyglutamic acid (Gla) domain with 9-12 Gla residues.
    Type: Grant
    Filed: November 22, 2005
    Date of Patent: September 17, 2013
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Michael Bech Jensen, Birthe Lykkegaard Hansen, Troels Kornfelt, Kirsten Kramer Jakobsen
  • Patent number: 8519103
    Abstract: Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: August 27, 2013
    Assignee: Catalyst Biosciences, Inc.
    Inventors: Edwin L. Madison, Christopher Thanos
  • Publication number: 20130209444
    Abstract: The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.
    Type: Application
    Filed: January 30, 2013
    Publication date: August 15, 2013
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Baxter International Inc., Baxter Healthcare S.A.
  • Patent number: 8497245
    Abstract: The invention provides methods of making and using compounds of the formula: or a pharmaceutically acceptable salt thereof; wherein n is an integer between 1 and 2 inclusively; m is an integer between 0 and 2 inclusively; X is selected from the group consisting of CH or N; R1 is selected from the group consisting of —CH2NH2, and R2 is selected from the group consisting of —H, —OH, —NH2 and acetyl; R3 is selected from the group consisting of —H, benzyloxycarbonyl and benzylsulfonyl; and R4 is selected from the group consisting of —OH, wherein p is an integer between 0 and 2 inclusively, Y is selected from the group consisting of —O—, —S—, —S(?O)—, —SO2—, methylene, —CH(OH)—, —CH(NH2)—, —CH(CH2—OH)—, —CH(CH2—NH2)— or —N(R6)—, R5 is selected from the group consisting of —H or a simple (C1-C3) alkyl and R6 is selected from the group consisting of —H, a simple (C1-C3) alkyl or a simple (C1-C3) acyl.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: July 30, 2013
    Assignee: The Medicines Company (Leipzig) GmbH
    Inventors: Peter Herold, Stjepan Jelakovic, Mohammed Daghish, Claudia Reichelt, Alexander Schulze, Andrea Schweinitz, Friedrich-Alexander Ludwig, Adel Rafai Far, Ting Kang
  • Patent number: 8486892
    Abstract: The invention relates to novel compounds with formula (I) X1-X2-X3-X4-X5-(X6)n-(X7)m-Y useful as blood coagulation factor inhibitors. The compounds (I) may be used for treatment of thrombotic conditions or as stabilizers of liquid formulations of blood coagulation factors, in particular liquid formulations of FVIIa, Factor VII variants, or Factor VII derivatives.
    Type: Grant
    Filed: January 22, 2009
    Date of Patent: July 16, 2013
    Assignee: Novo Nordisk Health Care AG
    Inventor: Florencio Zaragoza Dörwald
  • Patent number: 8476249
    Abstract: Invented is a method of treating thrombocytopenia in a human, in need thereof which comprises the in vivo administration of a therapeutically effective amount of a peptide or a non-peptide TPO receptor agonist and an anti-clotting agent or agents, and optional further active ingredients, to such human.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: July 2, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Connie L. Erickson-Miller, Michael Arning
  • Patent number: 8476234
    Abstract: Polypeptides and polynucleotides encoding same comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a coagulation factor and not to an amino terminus are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: July 2, 2013
    Assignee: Prolor Biotech Inc.
    Inventors: Udi Eyal Fima, Gili Hart
  • Patent number: 8461116
    Abstract: A liquid aqueous composition comprising (i) a factor VII polypeptide; (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an agent selected from the list of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the concentration of (iii) is at least 15 mM is described.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: June 11, 2013
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt
  • Patent number: 8461115
    Abstract: The present invention provides methods for the local treatment of bleeding in a subject and/or reducing unwanted effects associated with the systemic administration of thrombotic agents to a subject, by local administration of FVII to the subject.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: June 11, 2013
    Assignee: Stellaris Pharmaceuticals ApS
    Inventor: Lars Otto Uttenthal
  • Patent number: 8449884
    Abstract: The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: May 28, 2013
    Assignee: Syntonix Pharmaceuticals, Inc.
    Inventors: Daniel S. Rivera, Robert T. Peters, Alan J. Bitonti
  • Patent number: 8431535
    Abstract: The present invention provides methods for the local treatment of tracheal, bronchial or alveolar bleeding or hemoptysis and/or reducing unwanted effects associated with systemic administration of thrombotic agents to a subject via intratracheal, intrabronchial or intraalveolar administration of a blood coagulation factor to the subject.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: April 30, 2013
    Assignee: Hoiberg A/S
    Inventors: Lars Heslet, Lars Otto Uttenthal
  • Patent number: 8415458
    Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: April 9, 2013
    Assignee: Regents of the University of Minnesota
    Inventor: Gary L Nelsestuen
  • Publication number: 20130071383
    Abstract: A method of selectively introducing a substituent into a protein proximal to a binding site on the protein for a homing peptide, comprising: (a) contacting the protein with a compound comprising a homing peptide having the ability to bind to the binding site of the protein; and (b) allowing a moiety on the protein proximal to the binding site to react with the compound comprising the homing peptide, thereby to transfer the substituent G onto the protein.
    Type: Application
    Filed: April 12, 2011
    Publication date: March 21, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Mikael Kofod-Hansen, Henning Ralf Stennicke, Soeren Oestergaard, Henrik Oestergaard
  • Patent number: 8354377
    Abstract: The invention relates to a method for preventing or attenuating one or more complications of intracerebral haemorrhage (ICH), the method comprising: (i) selecting an ICH patient who exhibits one or more of the following characteristics: age?70, baseline ICH volume?60 mL, baseline IVH volume?5 mL, and elapsed time since onset of symptoms of less than about 2.5 hours; and (ii) administering to said patient in need thereof an effective amount of a first coagulation agent comprising Factor VIIa or a Factor VIIa equivalent.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: January 15, 2013
    Assignee: Novo Nordisk Health Care AG
    Inventors: Brett Skolnick, Nikolai Constantin Brun, Kamilla Begtrup
  • Patent number: 8299029
    Abstract: The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: October 30, 2012
    Assignee: Novo Nordisk Health Care AG
    Inventors: Michael Bech Jensen, Birthe Lykkegaard Hansen, Troels Kornfelt
  • Patent number: 8293234
    Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VIII to levels between 40 and 95%. The present invention further discloses pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: October 23, 2012
    Assignee: Life Sciences Research Partners
    Inventors: Jean-Marie Saint-Remy, Marc Jacquemin
  • Publication number: 20120052055
    Abstract: Invented is a method of treating thrombocytopenia in a human, in need thereof which comprises the in vivo administration of a therapeutically effective amount of a peptide or a non-peptide TPO receptor agonist and an anti-clotting agent or agents, and optional further active ingredients, to such human.
    Type: Application
    Filed: May 6, 2010
    Publication date: March 1, 2012
    Applicant: Glaxosmithkline LLC
    Inventors: Connie L. Erickson-Miller, Michael Arning
  • Publication number: 20120004176
    Abstract: A liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an agent selected from the list of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the concentration of (iii) is at least 15 mM.
    Type: Application
    Filed: September 14, 2011
    Publication date: January 5, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt
  • Patent number: 8062638
    Abstract: Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: November 22, 2011
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Saito, Takehisa Kitazawa, Kazutaka Yoshihashi, Kunihiro Hattori
  • Publication number: 20110280857
    Abstract: A sprayable polymeric foam hemostat for both compressible and non-compressible (intracavitary) acute wounds is disclosed. The foam comprises hydrophobically-modified polymers, such as hm-chitosan, or other amphiphilic polymers that anchor themselves within the membrane of cells in the vicinity of the wound. By rapidly expanding upon being released from a canister pressurized with liquefied gas propellant, the foam is able to enter injured body cavities and staunch bleeding. The seal created is strong enough to substantially prevent the loss of blood from these cavities. Hydrophobically-modified polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The amphiphilic polymers form solid gel networks with blood cells to create a physical clotting mechanism that prevent loss of blood.
    Type: Application
    Filed: November 15, 2010
    Publication date: November 17, 2011
    Inventors: Matthew Dowling, Srinivasa Raghavan
  • Publication number: 20110237512
    Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.
    Type: Application
    Filed: September 29, 2010
    Publication date: September 29, 2011
    Inventor: Kirk W. Johnson
  • Patent number: 8007795
    Abstract: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:FVIIa complex, effectively preventing factor X or FIX binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site. Also provided are humanized antibodies and fragments thereof that bind to the TF.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: August 30, 2011
    Assignee: Genentech, Inc.
    Inventors: Jin-an Jiao, Hing C. Wong, Esperanza Liliana Nieves, Luis A. Mosquera
  • Patent number: 7993644
    Abstract: The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the invention.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: August 9, 2011
    Assignee: Purdue Pharma L.P.
    Inventor: Baiyang Wang
  • Patent number: 7981865
    Abstract: Antigenic fragments of human Factor VIII polypeptide, pharmaceutical compositions which contain these fragments, and complexes containing these peptides and a carrier protein or peptide.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: July 19, 2011
    Assignee: Department Central De Fractionment De La Croix-Rouge Scrl
    Inventors: Ruth Laub, Mario Di Giambattista
  • Publication number: 20110172156
    Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.
    Type: Application
    Filed: January 13, 2011
    Publication date: July 14, 2011
    Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger
  • Patent number: 7968094
    Abstract: Disclosed is a method for preventing or treating thrombosis in a mammal such as a primate and particularly a human patient. A preferred method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to human tissue factor (TF). Additional methods and kits are provided.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: June 28, 2011
    Assignee: Genentech, Inc.
    Inventors: Jin-An Jiao, Hing C. Wong, Esperanza Liliana Nieves, Luis A. Mosquera
  • Publication number: 20110070288
    Abstract: The present invention is directed to a hemostatic composite structure having a bioabsorbable fabric or non-woven substrate having at least two major oppositely facing surface areas and a continuous non-porous polymer-based film that is laminated on one major surface of said substrate. The bioabsorbable fabric substrate can be an oxidized polysaccharide and/or the non-woven substrate can be made from bioabsorbable, non-cellulosic derived polymers. The continuous non-porous polymer based film can be a bioabsorbable polymer. The present invention also relates to a method for providing hemostasis by applying a composite structure described herein onto a wound site in need of a hemostatic device wherein a major surface of the substrate without the film layer is applied onto the wound site.
    Type: Application
    Filed: September 22, 2009
    Publication date: March 24, 2011
    Inventor: SASA ANDJELIC
  • Publication number: 20110059894
    Abstract: The invention provides a method for preventing formation of inhibitors to blood coagulation factor VIII or factor IX in a subject having haemophilia, the method comprising administering (via intravenous, subcutaneous, intradermal, or intramuscular routes) to a previously untreated subject an effective dosage of factor VIIa or a factor VII-related polypeptide.
    Type: Application
    Filed: November 12, 2010
    Publication date: March 10, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Lisa Payne Rojkjaer, Marie Johannessen, Ole Juul Nordfang, Jens Aas Jansen
  • Patent number: 7879803
    Abstract: This application describes methods of treatment involving a protease for activating the blood clotting factor VII, which (a) activates blood clotting factor VII, (b) is inhibited by the presence of aprotinin, (c) is increased in its activity by the presence of at least one of the following: calcium ions, heparin, or heparin related substances, and (d) in SDS-PAGE, on subsequent staining in the non-reduced state, has one or more bands in the molecular weight range from 50 to 75 kDa, and in the reduced state has a band at 40 to 55 kDa and one or more bands in the molecular weight range from 10 to 35 kDa, and a band, which corresponds to a proenzyme, in the molecular weight range from 60 to 65 kDa.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: February 1, 2011
    Assignee: CSL Behring GmbH
    Inventors: Jürgen Römisch, Annette Feussner, Hans-Arnold Stöhr